The treatment of aggressive prolactinomas with everolimus
Authors' conclusion
Everolimus is an active agent in the treatment of prolactinomas that warrants further investigation.
Study context
- Population
- Patients with aggressive prolactinomas who progressed following a dopamine receptor agonist, radiotherapy and temozolomide
- Participants
- 4 patients
- Outcome
- Response to everolimus
Methodological detailssingle-institution database review
- Single-institution database review
Main finding
As reported in the abstract
Biochemical response
3 of 4 patients
Clinically meaningful benefit (suppression of tumor growth)
4 of 4 patients
Best overall response by Response Assessments in Neuro-Oncology (RANO) criteria: stable disease
4 of 4 patients
Minor regression in tumor size
2 of 4 patients
Observational data: associations, not effects.
Original publication
The treatment of aggressive prolactinomas with everolimus. Pituitary. Published 10 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →